Table 1.
IC50 and standard errors for HNSCC cell lines after treatment with MK2206 plus cetuximab for 72h.
| Cell line | Condition | IC50 MK2206 (µM) | P-value |
|---|---|---|---|
| SC263-S | MK2206 | 3.311 ± 0.537 | – |
| MK2206 + 25 nM cetuximab | 1.816 ± 0.134 | 0.068 | |
| MK2206 + 50 nM cetuximab | 1.609 ± 0.154 | 0.048 | |
| SCC22b-S | MK2206 | 3.086 ± 0.239 | – |
| MK2206 + 25 nM cetuximab | 1.749 ± 0.120 | 0.006 | |
| MK2206 + 50 nM cetuximab | 1.646 ± 0.101 | 0.004 | |
| SC263-R | MK2206 | 4.764 ± 0.436 | – |
| MK2206 + 25 nM cetuximab | 2.545 ± 0.135 | 0.015 | |
| MK2206 + 50 nM cetuximab | 2.212 ± 0.109 | 0.010 | |
| SCC22b-R | MK2206 | 1.752 ± 0.084 | – |
| MK2206 + 25 nM cetuximab | 1.446 ± 0.085 | 0.020 | |
| MK2206 + 50 nM cetuximab | 1.327 ± 0.082 | 0.006 |
P < 0.050, significant difference in IC50 compared to MK2206 monotherapy. P < 0.050 are indicated in bold. -, cannot be calculated. Suffix -S: cetuximab sensitive cell line and suffix -R: acquired cetuximab resistant cell line.